Nanolyze
Provides new ultra-sensitive technology for analyzing nanoparticle uptake and release of substances.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
* | SEK11.0m | Early VC | |
| Total Funding | 000k | ||
| SEK | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (80 %) | (10 %) | 7833 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (18 %) | (2139 %) | (4104 %) | (13 %) |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Nanolyze provides new ultra-sensitive technology for analyzing nanoparticle uptake and release of substances. A necessary step for making future medicine more precise and efficient.
Nanolyze is a research startup and our first line of products will be on the market in 2021. Our focus is both labs with high throughput requiring efficient automatized processes, and labs with fewer experiments, but need for low investment cost. Our system is scalable with the same unique capabilities for all setups. By putting the right pieces together, we will provide the optimal solution for industrial applications with high throughput as well as fundamental research applications with few measurements with detailed and precise output.